Share Price and Basic Stock Data
Last Updated: January 6, 2026, 8:36 pm
| PEG Ratio | 3.44 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Alkosign Ltd operates within an undisclosed industry, with its current market capitalization standing at ₹82.6 Cr. The company’s share price is ₹76.5, reflecting a price-to-earnings (P/E) ratio of 97.1. Over the past quarters, Alkosign has shown significant revenue growth, with sales increasing from ₹4.03 Cr in September 2021 to ₹21.25 Cr by September 2023. This upward trajectory continued into the first half of FY 2025, where reported sales reached ₹14.43 Cr in March 2024 and ₹27.90 Cr in September 2024. The operating profit margins (OPM) fluctuated significantly during this period, peaking at 40.47% in September 2023 before declining to 7.40% by September 2025. This volatility in revenue and profitability indicates that the company is navigating a dynamic market environment, possibly influenced by operational challenges or competitive dynamics.
Profitability and Efficiency Metrics
Alkosign’s profitability metrics reveal a mixed performance. The net profit reported for the quarter ending September 2023 stood at ₹5.80 Cr, a significant recovery from previous losses. However, for the year ending March 2025, net profit is projected at ₹0.85 Cr, reflecting a decline from ₹3.77 Cr in the previous year. The company recorded a return on equity (ROE) of 12.0% and a return on capital employed (ROCE) of 12.8%, which are relatively modest compared to industry standards. Efficiency ratios indicate an improvement, with the cash conversion cycle (CCC) at 240.36 days. While this represents a tightening from previous periods, it remains high compared to typical sector norms. Operating profit margins averaged around 15.76% for the fiscal year 2025, showcasing potential for operational efficiency but also highlighting areas for improvement in cost management.
Balance Sheet Strength and Financial Ratios
Alkosign’s balance sheet reflects a conservative capital structure, with total borrowings amounting to ₹13.41 Cr against reserves of ₹22.59 Cr as of September 2025. The company’s interest coverage ratio (ICR) stands at 7.47x, indicating a strong ability to meet interest obligations, which is a positive sign for creditors and investors alike. The price-to-book value (P/BV) ratio is recorded at 2.09x, suggesting that the market values the company at a premium relative to its book value. The current ratio is a healthy 2.54, indicating strong liquidity. However, the total debt-to-equity ratio at 0.38 indicates a moderate level of leverage, which could pose risks in a rising interest rate environment. Overall, while Alkosign shows signs of financial resilience, the balance sheet’s leverage needs careful monitoring.
Shareholding Pattern and Investor Confidence
As of September 2025, Alkosign boasts a diverse shareholding structure with promoters holding 43.35% of the equity, indicating a significant insider commitment. Foreign institutional investors (FIIs) hold 9.94%, while domestic institutional investors (DIIs) account for 3.35%. Public shareholders represent 43.36%, reflecting a balanced distribution of ownership. This mix can enhance liquidity and investor confidence. The number of shareholders has shown volatility, reducing from 757 in September 2024 to 615 in September 2025, which may raise concerns about retail investor interest. The gradual increase in promoter holdings from 40.32% in March 2024 to 43.35% in September 2025 may signal a positive outlook from insiders, potentially boosting market sentiment. However, the decline in public shareholder numbers could indicate a need for improved investor communication strategies.
Outlook, Risks, and Final Insight
Looking ahead, Alkosign Ltd faces both opportunities and challenges. The company’s impressive revenue growth trajectory indicates potential for market expansion, but the volatility in profit margins and net income poses risks. Key strengths include a solid interest coverage ratio and increasing promoter confidence, which may bolster investor sentiment. Conversely, high cash conversion cycles and fluctuating profitability margins present operational risks that could impact future performance. In a scenario where operational efficiencies are enhanced, and market conditions remain favorable, Alkosign could solidify its growth trajectory. However, if economic conditions deteriorate or operational challenges persist, the company may face significant headwinds. Strategic focus on cost management and enhancing shareholder value will be crucial for sustaining growth and confidence in the future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 100 Cr. | 26.3 | 784/25.8 | 0.98 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 1,793 Cr. | 176 | 212/124 | 118 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 46.0 Cr. | 3.61 | 8.19/3.42 | 4.93 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 7,792.00 Cr | 220.13 | 388.50 | 219.27 | 0.25% | 11.73% | 22.92% | 9.00 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.03 | 6.13 | 9.11 | 12.27 | 21.25 | 14.43 | 27.90 | 23.63 | 26.34 |
| Expenses | 3.38 | 5.91 | 8.18 | 10.38 | 12.65 | 18.52 | 23.06 | 20.67 | 24.39 |
| Operating Profit | 0.65 | 0.22 | 0.93 | 1.89 | 8.60 | -4.09 | 4.84 | 2.96 | 1.95 |
| OPM % | 16.13% | 3.59% | 10.21% | 15.40% | 40.47% | -28.34% | 17.35% | 12.53% | 7.40% |
| Other Income | 0.00 | 0.06 | 0.03 | 0.22 | 0.04 | 0.24 | 0.15 | 0.16 | 0.16 |
| Interest | 0.40 | 0.44 | 0.64 | 0.87 | 0.45 | 1.22 | 0.51 | 0.57 | 0.60 |
| Depreciation | 0.69 | 0.97 | 0.94 | 1.00 | 1.20 | 1.25 | 1.17 | 1.25 | 1.11 |
| Profit before tax | -0.44 | -1.13 | -0.62 | 0.24 | 6.99 | -6.32 | 3.31 | 1.30 | 0.40 |
| Tax % | -6.82% | -15.04% | 1.61% | 25.00% | 17.02% | -20.73% | 0.00% | 65.38% | 0.00% |
| Net Profit | -0.41 | -0.96 | -0.63 | 0.18 | 5.80 | -5.02 | 3.31 | 0.46 | 0.39 |
| EPS in Rs | -1.17 | -0.77 | 0.22 | 5.37 | -4.65 | 3.06 | 0.43 | 0.36 |
Last Updated: December 28, 2025, 6:01 am
Below is a detailed analysis of the quarterly data for Alkosign Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 26.34 Cr.. The value appears strong and on an upward trend. It has increased from 23.63 Cr. (Mar 2025) to 26.34 Cr., marking an increase of 2.71 Cr..
- For Expenses, as of Sep 2025, the value is 24.39 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.67 Cr. (Mar 2025) to 24.39 Cr., marking an increase of 3.72 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.95 Cr.. The value appears to be declining and may need further review. It has decreased from 2.96 Cr. (Mar 2025) to 1.95 Cr., marking a decrease of 1.01 Cr..
- For OPM %, as of Sep 2025, the value is 7.40%. The value appears to be declining and may need further review. It has decreased from 12.53% (Mar 2025) to 7.40%, marking a decrease of 5.13%.
- For Other Income, as of Sep 2025, the value is 0.16 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.16 Cr..
- For Interest, as of Sep 2025, the value is 0.60 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.57 Cr. (Mar 2025) to 0.60 Cr., marking an increase of 0.03 Cr..
- For Depreciation, as of Sep 2025, the value is 1.11 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.25 Cr. (Mar 2025) to 1.11 Cr., marking a decrease of 0.14 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.40 Cr.. The value appears to be declining and may need further review. It has decreased from 1.30 Cr. (Mar 2025) to 0.40 Cr., marking a decrease of 0.90 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 65.38% (Mar 2025) to 0.00%, marking a decrease of 65.38%.
- For Net Profit, as of Sep 2025, the value is 0.39 Cr.. The value appears to be declining and may need further review. It has decreased from 0.46 Cr. (Mar 2025) to 0.39 Cr., marking a decrease of 0.07 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.36. The value appears to be declining and may need further review. It has decreased from 0.43 (Mar 2025) to 0.36, marking a decrease of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:16 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 13.24 | 13.24 | 10.16 | 21.38 | 35.69 | 51.53 | 49.97 |
| Expenses | 11.85 | 11.85 | 9.28 | 18.55 | 31.18 | 43.72 | 45.06 |
| Operating Profit | 1.39 | 1.39 | 0.88 | 2.83 | 4.51 | 7.81 | 4.91 |
| OPM % | 10.50% | 10.50% | 8.66% | 13.24% | 12.64% | 15.16% | 9.83% |
| Other Income | 0.03 | 0.03 | 0.05 | 0.25 | 0.28 | 0.32 | 0.32 |
| Interest | 0.31 | 0.31 | 0.84 | 1.51 | 1.67 | 1.09 | 1.17 |
| Depreciation | 0.20 | 0.20 | 1.66 | 1.95 | 2.45 | 2.42 | 2.36 |
| Profit before tax | 0.91 | 0.91 | -1.57 | -0.38 | 0.67 | 4.62 | 1.70 |
| Tax % | 27.47% | 27.47% | -12.74% | 21.05% | -16.42% | 18.40% | |
| Net Profit | 0.66 | 0.66 | -1.38 | -0.46 | 0.78 | 3.77 | 0.85 |
| EPS in Rs | -1.68 | -0.56 | 0.72 | 3.49 | 0.79 | ||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 9.23% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -309.09% | 66.67% | 269.57% | 383.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -309.09% | 375.76% | 202.90% | 113.77% |
Alkosign Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 72% |
| TTM: | 44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 42% |
| 3 Years: | 68% |
| TTM: | 409% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 22% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 2:11 pm
Balance Sheet
Last Updated: December 4, 2025, 2:20 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 5.45 | 5.45 | 7.20 | 7.20 | 10.79 |
| Reserves | 0.66 | 0.66 | 7.17 | 6.71 | 22.02 | 25.79 | 22.59 |
| Borrowings | 20.47 | 20.47 | 16.03 | 20.40 | 13.85 | 12.55 | 13.41 |
| Other Liabilities | 2.52 | 2.37 | 0.88 | 2.23 | 6.76 | 5.51 | 7.95 |
| Total Liabilities | 23.66 | 23.51 | 29.53 | 34.79 | 49.83 | 51.05 | 54.74 |
| Fixed Assets | 1.56 | 1.56 | 15.95 | 18.35 | 16.93 | 16.31 | 16.94 |
| CWIP | 14.28 | 14.28 | 0.00 | 0.00 | 0.61 | 0.54 | 0.00 |
| Investments | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.00 | 0.00 |
| Other Assets | 7.72 | 7.57 | 13.48 | 16.34 | 32.19 | 34.20 | 37.80 |
| Total Assets | 23.66 | 23.51 | 29.53 | 34.79 | 49.83 | 51.05 | 54.74 |
Below is a detailed analysis of the balance sheet data for Alkosign Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.79 Cr.. The value appears strong and on an upward trend. It has increased from 7.20 Cr. (Mar 2025) to 10.79 Cr., marking an increase of 3.59 Cr..
- For Reserves, as of Sep 2025, the value is 22.59 Cr.. The value appears to be declining and may need further review. It has decreased from 25.79 Cr. (Mar 2025) to 22.59 Cr., marking a decrease of 3.20 Cr..
- For Borrowings, as of Sep 2025, the value is 13.41 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 12.55 Cr. (Mar 2025) to 13.41 Cr., marking an increase of 0.86 Cr..
- For Other Liabilities, as of Sep 2025, the value is 7.95 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.51 Cr. (Mar 2025) to 7.95 Cr., marking an increase of 2.44 Cr..
- For Total Liabilities, as of Sep 2025, the value is 54.74 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 51.05 Cr. (Mar 2025) to 54.74 Cr., marking an increase of 3.69 Cr..
- For Fixed Assets, as of Sep 2025, the value is 16.94 Cr.. The value appears strong and on an upward trend. It has increased from 16.31 Cr. (Mar 2025) to 16.94 Cr., marking an increase of 0.63 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.54 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.54 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 37.80 Cr.. The value appears strong and on an upward trend. It has increased from 34.20 Cr. (Mar 2025) to 37.80 Cr., marking an increase of 3.60 Cr..
- For Total Assets, as of Sep 2025, the value is 54.74 Cr.. The value appears strong and on an upward trend. It has increased from 51.05 Cr. (Mar 2025) to 54.74 Cr., marking an increase of 3.69 Cr..
Notably, the Reserves (22.59 Cr.) exceed the Borrowings (13.41 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -19.08 | -19.08 | -15.15 | -17.57 | -9.34 | -4.74 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 137.56 | 137.56 | 83.71 | 47.12 | 57.58 | 84.57 |
| Inventory Days | 115.21 | 115.21 | 202.07 | 267.67 | 278.07 | 203.40 |
| Days Payable | 98.90 | 98.90 | 31.43 | 32.54 | 97.88 | 47.61 |
| Cash Conversion Cycle | 153.88 | 153.88 | 254.34 | 282.25 | 237.77 | 240.36 |
| Working Capital Days | -164.03 | -163.20 | -105.26 | -14.00 | 109.33 | 120.13 |
| ROCE % | 5.77% | -2.89% | 3.69% | 6.06% | 12.78% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 5.24 | 1.22 |
| Diluted EPS (Rs.) | 5.24 | 1.22 |
| Cash EPS (Rs.) | 8.60 | 4.50 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 45.84 | 40.61 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 45.84 | 40.61 |
| Revenue From Operations / Share (Rs.) | 71.62 | 49.60 |
| PBDIT / Share (Rs.) | 11.29 | 6.66 |
| PBIT / Share (Rs.) | 7.93 | 3.25 |
| PBT / Share (Rs.) | 6.42 | 0.92 |
| Net Profit / Share (Rs.) | 5.24 | 1.09 |
| NP After MI And SOA / Share (Rs.) | 5.24 | 1.09 |
| PBDIT Margin (%) | 15.76 | 13.41 |
| PBIT Margin (%) | 11.07 | 6.54 |
| PBT Margin (%) | 8.96 | 1.86 |
| Net Profit Margin (%) | 7.31 | 2.19 |
| NP After MI And SOA Margin (%) | 7.31 | 2.19 |
| Return on Networth / Equity (%) | 11.42 | 2.68 |
| Return on Capital Employeed (%) | 15.05 | 6.57 |
| Return On Assets (%) | 7.38 | 1.57 |
| Long Term Debt / Equity (X) | 0.14 | 0.21 |
| Total Debt / Equity (X) | 0.38 | 0.47 |
| Asset Turnover Ratio (%) | 1.02 | 0.00 |
| Current Ratio (X) | 2.54 | 2.21 |
| Quick Ratio (X) | 1.24 | 1.07 |
| Inventory Turnover Ratio (X) | 3.09 | 0.00 |
| Interest Coverage Ratio (X) | 7.47 | 2.87 |
| Interest Coverage Ratio (Post Tax) (X) | 4.46 | 1.47 |
| Enterprise Value (Cr.) | 78.34 | 130.32 |
| EV / Net Operating Revenue (X) | 1.52 | 3.65 |
| EV / EBITDA (X) | 9.64 | 27.21 |
| MarketCap / Net Operating Revenue (X) | 1.34 | 3.45 |
| Price / BV (X) | 2.09 | 4.21 |
| Price / Net Operating Revenue (X) | 1.34 | 3.45 |
| EarningsYield | 0.05 | 0.01 |
After reviewing the key financial ratios for Alkosign Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.22 (Mar 24) to 5.24, marking an increase of 4.02.
- For Diluted EPS (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.22 (Mar 24) to 5.24, marking an increase of 4.02.
- For Cash EPS (Rs.), as of Mar 25, the value is 8.60. This value is within the healthy range. It has increased from 4.50 (Mar 24) to 8.60, marking an increase of 4.10.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 45.84. It has increased from 40.61 (Mar 24) to 45.84, marking an increase of 5.23.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 45.84. It has increased from 40.61 (Mar 24) to 45.84, marking an increase of 5.23.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 71.62. It has increased from 49.60 (Mar 24) to 71.62, marking an increase of 22.02.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.29. This value is within the healthy range. It has increased from 6.66 (Mar 24) to 11.29, marking an increase of 4.63.
- For PBIT / Share (Rs.), as of Mar 25, the value is 7.93. This value is within the healthy range. It has increased from 3.25 (Mar 24) to 7.93, marking an increase of 4.68.
- For PBT / Share (Rs.), as of Mar 25, the value is 6.42. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 6.42, marking an increase of 5.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 5.24, marking an increase of 4.15.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 5.24, marking an increase of 4.15.
- For PBDIT Margin (%), as of Mar 25, the value is 15.76. This value is within the healthy range. It has increased from 13.41 (Mar 24) to 15.76, marking an increase of 2.35.
- For PBIT Margin (%), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 6.54 (Mar 24) to 11.07, marking an increase of 4.53.
- For PBT Margin (%), as of Mar 25, the value is 8.96. This value is below the healthy minimum of 10. It has increased from 1.86 (Mar 24) to 8.96, marking an increase of 7.10.
- For Net Profit Margin (%), as of Mar 25, the value is 7.31. This value is within the healthy range. It has increased from 2.19 (Mar 24) to 7.31, marking an increase of 5.12.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.31. This value is below the healthy minimum of 8. It has increased from 2.19 (Mar 24) to 7.31, marking an increase of 5.12.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.42. This value is below the healthy minimum of 15. It has increased from 2.68 (Mar 24) to 11.42, marking an increase of 8.74.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.05. This value is within the healthy range. It has increased from 6.57 (Mar 24) to 15.05, marking an increase of 8.48.
- For Return On Assets (%), as of Mar 25, the value is 7.38. This value is within the healthy range. It has increased from 1.57 (Mar 24) to 7.38, marking an increase of 5.81.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 0.2. It has decreased from 0.21 (Mar 24) to 0.14, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has decreased from 0.47 (Mar 24) to 0.38, marking a decrease of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.02. It has increased from 0.00 (Mar 24) to 1.02, marking an increase of 1.02.
- For Current Ratio (X), as of Mar 25, the value is 2.54. This value is within the healthy range. It has increased from 2.21 (Mar 24) to 2.54, marking an increase of 0.33.
- For Quick Ratio (X), as of Mar 25, the value is 1.24. This value is within the healthy range. It has increased from 1.07 (Mar 24) to 1.24, marking an increase of 0.17.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.09. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 3.09, marking an increase of 3.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.47. This value is within the healthy range. It has increased from 2.87 (Mar 24) to 7.47, marking an increase of 4.60.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.46. This value is within the healthy range. It has increased from 1.47 (Mar 24) to 4.46, marking an increase of 2.99.
- For Enterprise Value (Cr.), as of Mar 25, the value is 78.34. It has decreased from 130.32 (Mar 24) to 78.34, marking a decrease of 51.98.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.52. This value is within the healthy range. It has decreased from 3.65 (Mar 24) to 1.52, marking a decrease of 2.13.
- For EV / EBITDA (X), as of Mar 25, the value is 9.64. This value is within the healthy range. It has decreased from 27.21 (Mar 24) to 9.64, marking a decrease of 17.57.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 3.45 (Mar 24) to 1.34, marking a decrease of 2.11.
- For Price / BV (X), as of Mar 25, the value is 2.09. This value is within the healthy range. It has decreased from 4.21 (Mar 24) to 2.09, marking a decrease of 2.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 3.45 (Mar 24) to 1.34, marking a decrease of 2.11.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alkosign Ltd:
- Net Profit Margin: 7.31%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.05% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.42% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.24
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 97.1 (Industry average Stock P/E: 388.5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.38
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.31%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Printing/Publishing/Stationery | Plot No. 12-A, MIDC, NR Mother Dairy, Thane Maharashtra 421311 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Samir Narendra Shah | Chairman & Managing Director |
| Mr. Shrenik Kamlesh Shah | Whole Time Director |
| Mr. Akshay Narendra Shah | Non Executive Director |
| Ms. Zeenal Shrenik Shah | Non Executive Director |
| Mr. Parshva Vinaykant Doshi | Ind. Non-Executive Director |
| Mr. Yogesh Ramgopal Gupta | Ind. Non-Executive Director |
| Ms. Seema Ashim Jhaveri | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Alkosign Ltd?
Alkosign Ltd's intrinsic value (as of 07 January 2026) is ₹293.80 which is 284.05% higher the current market price of ₹76.50, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹82.6 Cr. market cap, FY2025-2026 high/low of ₹96.7/46.0, reserves of ₹22.59 Cr, and liabilities of ₹54.74 Cr.
What is the Market Cap of Alkosign Ltd?
The Market Cap of Alkosign Ltd is 82.6 Cr..
What is the current Stock Price of Alkosign Ltd as on 07 January 2026?
The current stock price of Alkosign Ltd as on 07 January 2026 is ₹76.5.
What is the High / Low of Alkosign Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Alkosign Ltd stocks is ₹96.7/46.0.
What is the Stock P/E of Alkosign Ltd?
The Stock P/E of Alkosign Ltd is 97.1.
What is the Book Value of Alkosign Ltd?
The Book Value of Alkosign Ltd is 30.9.
What is the Dividend Yield of Alkosign Ltd?
The Dividend Yield of Alkosign Ltd is 0.00 %.
What is the ROCE of Alkosign Ltd?
The ROCE of Alkosign Ltd is 12.8 %.
What is the ROE of Alkosign Ltd?
The ROE of Alkosign Ltd is 12.0 %.
What is the Face Value of Alkosign Ltd?
The Face Value of Alkosign Ltd is 10.0.